Ryoichi Ishibashi

17PUBLICATIONS
34CO-AUTHORS
PharmacogenomicsOptical technologyGene and molecular therapyMolecular targetsFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 12, 2026
Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study.

|May 03, 2026
Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post-hoc Analysis of the COMET Trial.

|Aug 04, 2025
Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial.

Tomoaki Tatsumi, Yoko Takatsuna, Ryoichi Ishibashi

|Feb 12, 2025
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.

Ryoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka

|Jan 14, 2025
Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study.

Kiichi Hirayama, Masaya Koshizaka, Ryoichi Ishibashi

|Aug 02, 2024
Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.

Yusuke Baba, Suzuka Watanabe, Saho Hayashi

Pageof 3

Frequent Collaborators

10 joint publications

Masaya Koshizaka

9 joint publications

Koutaro Yokote

2 joint publications

Kengo Nagashima

2 joint publications

Yoshiro Maezawa